Evidence map›Paper›PMID 33723627›Full record

ArticleAnalytical and bioanalytical chemistry2021

High-resolution AP-SMALDI MSI as a tool for drug imaging in Schistosoma mansoni.

Annika S Mokosch, Stefanie Gerbig, Christoph G Grevelding, Simone Haeberlein, Bernhard Spengler

Open access · hybridAbstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Mass Spectrometry Imaging of Lipid and Metabolite Distributions in Cysts ofJournal of the American Society for Mass Spectrometry · 2025
    Article
  7. Article
  8. Spatial pharmacology using mass spectrometry imaging.Trends in pharmacological sciences · 2024
    Review
  9. Review
  10. Review
  11. Negative Ion-Mode N-Glycan Mass Spectrometry Imaging by MALDI-2-TOF-MS.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Annika S MokoschInstitute of Inorganic and Analytical Chemistry, Justus Liebig University Giessen, 35392, Giessen, Germany.
Stefanie GerbigInstitute of Inorganic and Analytical Chemistry, Justus Liebig University Giessen, 35392, Giessen, Germany.
Christoph G GreveldingInstitute of Parasitology, BFS, Justus Liebig University Giessen, 35392, Giessen, Germany.
Simone HaeberleinInstitute of Parasitology, BFS, Justus Liebig University Giessen, 35392, Giessen, Germany.
Bernhard SpenglerInstitute of Inorganic and Analytical Chemistry, Justus Liebig University Giessen, 35392, Giessen, Germany. Bernhard.Spengler@anorg.chemie.uni-giessen.de.
University of Giessen · DE

Funding

Deutsche Forschungsgemeinschaft Sp314/13-1State of Hesse, Ministry of Science, Higher Education and Art (HMWK) LOEWE Center DRUID
6 · The paper itself

Abstract

Schistosoma mansoni is a parasitic flatworm causing schistosomiasis, an infectious disease affecting several hundred million people worldwide. Schistosomes live dioeciously, and upon pairing with the male, the female starts massive egg production, which causes pathology. Praziquantel (PZQ) is the only drug used, but it has an inherent risk of resistance development. Therefore, alternatives are needed. In the context of drug repurposing, the cancer drug imatinib was tested, showing high efficacy against S. mansoni in vitro. Besides the gonads, imatinib mainly affected the integrity of the intestine in males and females. In this study, we investigated the potential uptake and distribution of imatinib in adult schistosomes including its distribution kinetics. To this end, we applied for the first time atmospheric-pressure scanning microprobe matrix-assisted laser desorption/ionization mass spectrometry imaging (AP-SMALDI MSI) for drug imaging in paired S. mansoni. Our results indicate that imatinib was present in the esophagus and intestine of the male as early as 20 min after in vitro exposure, suggesting an oral uptake route. After one hour, the drug was also found inside the paired female. The detection of the main metabolite, N-desmethyl imatinib, indicated metabolization of the drug. Additionally, a marker signal for the female ovary was successfully applied to facilitate further conclusions regarding organ tropism of imatinib. Our results demonstrate that AP-SMALDI MSI is a useful method to study the uptake, tissue distribution, and metabolization of imatinib in S. mansoni. The results suggest using AP-SMALDI MSI also for investigating other antiparasitic compounds and their metabolites in schistosomes and other parasites.

Indexed as

AnimalsAntineoplastic AgentsAntiparasitic AgentsDrug RepositioningFemaleImatinib MesylateMaleMesocricetusSchistosoma mansoniSchistosomiasis mansoniSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntineoplastic AgentsAntiparasitic AgentsImatinib MesylateDrug imagingDrug repurposingImatinibMALDI mass spectrometry imagingNeglected tropical diseasesSchistosoma mansoni

Identifiers

PMID33723627
PMCPMC8007518
OpenAlexW3136551495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.